Clinical Trials Directory

Trials / Unknown

UnknownNCT03267771

Progesterone and Doppler in Recurrent Abortion

Role of Serum Progesterone and Doppler Ultrasound in Prediction of Pregnancy Outcome in Women With Recurrent Unexplained Abortion

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
Female
Age
18 Years – 35 Years
Healthy volunteers
Accepted

Summary

Recurrent pregnancy loss is classically defined as the occurrence of three or more consecutive pregnancy loss. The American Society of Reproductive Medicine has recently redefined recurrent pregnancy loss as two or more pregnancy losses. A pregnancy loss is defined as a clinically-recognized pregnancy means that the pregnancy has been visualized on an ultrasound or that pregnancy tissue was identified after a pregnancy loss.

Detailed description

Spontaneous pregnancy loss is a surprisingly common occurrence. Whereas approximately 15% of all clinically recognized pregnancies result in spontaneous loss, there are many more pregnancies that fail prior to being clinically recognized. Only 30% of all conceptions result in a live birth. Although no reliable published data have estimated the probability of finding an etiology for recurrent pregnancy loss in a population with 2 versus 3 or more miscarriages, the best available data suggest that the risk of miscarriage in subsequent pregnancies is 30% after 2 losses, compared with 33% after 3 losses among patients without a history of a live birth. This strongly suggests a role for evaluation after just 2 losses in patients with no prior live births. An earlier evaluation may be further indicated if fetal cardiac activity was identified prior to a loss .

Conditions

Interventions

TypeNameDescription
DRUGProgesterone Suppositories Vaginalprogesterone vaginal suppository
DRUGDydrogesterone Oral Tabletoral progesterone drug
DEVICEdoppler ultrasoundpulsed doppler ultrasound

Timeline

Start date
2017-10-01
Primary completion
2019-08-05
Completion
2019-12-05
First posted
2017-08-30
Last updated
2017-09-08

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03267771. Inclusion in this directory is not an endorsement.